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Antiplatelet effect of aspirin in patients with cerebrovascular disease
Alberts MJ, Bergman DL, Molner E, et al. Stroke 2004;35:175-8.
Conclusion: More than half of patients taking enteric-coated aspiri-
n(ASA) or low-dose ASA have normal platelet function. Women and older
patients are less likely to have a positive therapeutic response to aspirin
independent of aspirin formulation or dose.
Summary: Platelet function in patients with cerebrovascular disease
who were taking only ASA as an antiplatelet agent was analyzed. A
platelet function analyzer (PFA-100), a commercially available benchtop
device, was used to evaluate platelet function. ASA dose, formulation,
and basic demographic factors were correlated with PFA platelet function
results.
One hundred and twenty-nine patients with a diagnosis of stroke,
transient ischemic attack, or cerebrovascular disease were entered in the
study. A total of 39 patients were taking 81 mg of ASA every other day or
daily. Of these, 22 (56%) had normal PFA results. Normal PFAs were also
present in 24 of 87 patients (28%) taking 325 mg per day of ASA, (P 
.001). An enteric-coated form of ASA was taken by 41 patients (32%).
ASA resistance was 65% in patients taking an enteric-coated ASA prepa-
ration. ASA resistance was 25% in patients taking uncoated ASA prepa-
rations, (P  .001). Patients older than 63 years had a decreased
therapeutic response to ASA independent of dose (P  .048) and
preparation (P  .034). Men had a stronger association between ASA
dose and a therapeutic PFA response than women (odds ratio, 5 versus
2.5).
Comment: Up to 40% of patients with stroke are taking ASA at the
time of their event (Stroke 2001;32:2559-66). Failure of ASA therapy to
prevent stroke may be related to patient compliance, drug interactions,
and stroke mechanisms not responsive to ASA or ASA resistance. This
study is critical in that it indicates that ASA resistance may be in part due
to the dosage and formulation of ASA. In addition, older patients and
women may be less likely to respond to ASA therapy. Demographic
factors may identify patients with cerebrovascular disease who should be
preferentially treated with antiplatelet agents other than ASA.
A polymer-based, paclitaxel-eluting stent in patients with coronary
artery disease
Stone GW, Ellis SG, Cox DA, TAXUS-IV Investigators. N Engl J Med
2004;350:221-31.
Conclusion: Compared with bare metal stents, paclitaxel-eluting
stents markedly reduce angiographic and clinical restenosis at 9 months
following coronary stenting procedures.
Summary: This was a randomized, prospective, double-blind, multi-
center trial conducted at 73 US centers. Patients with previously untreated
coronary artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length,
10-28 mm) who were to receive a stent for a single previously untreated
coronary artery stenosis were randomly allocated to receive a bare metal stent
or a paclitaxel-eluting stent. A total of 652 patients received the bare metal
stent and 662 received the drug eluting stent. At 9 months, angiographic
follow-up was prespecified in 732 patients.
Mean vessel diameter was 2.7 mm, mean lesion length was 13.4 mm,
and diabetes was present in 24.2% of patients. At 9 months, ischemia-driven
target vessel revascularization was 12.0% in the patients treated with bare
metal stents and 4.7% in patients treated with the drug-eluting stent (relative
risk, 0.39; 95% confidence interval, 0.26-0.59; P  .001). Target lesion
revascularization was also significantly less in the drug-eluting stent group
than in the bare metal stent group (3.0% versus 11.3%; relative risk 0.27; 95%
confidence interval, 0.16-0.43; P  .001). Angiographic restenosis was
reduced in the drug-eluting stent patients (7.9% versus 26.6%; P  .001).
Stent thrombosis occurred in 0.6% of the patients receiving a drug-eluting
stent and 0.8% of the patients receiving a bare metal stent.
Comment: Paclitaxel inhibits cellular division, signal transduction, and
motility. Its effect on coronary artery restenosis when delivered via a coro-
nary artery stent appears similar to that of sirolimus delivered via coronary
stents. Cardiologists now have two drug-eluting stents from which to
choose. It appears reasonable, and likely, that both types of drug-eluting
stents will eventually be evaluated in peripheral arteries as well.
Explaining racial variation in lower extremity amputation: A five-year
retrospective claims data and medical record review at an urban teach-
ing hospital
Rucker-Whitaker C, Feinglass J, Pearce WH. Arch Surg 2003;138:1347-51.
Conclusion: Racial disparities in amputation rates between African
American patients and white patients are due to higher rates of repeat
amputation among African American patients and not a higher rate of
primary amputation.
Summary: Population-based data suggests African American patients
undergo major lower extremity amputation up to three times more fre-
quently than white patients. To determine whether this disparity is due to
treatment choice or severity of disease, the authors studied rates of primary
major amputation and repeat amputation at a large Midwestern teaching
hospital. The risk of primary amputation was derived from analyzing data for
all patients undergoing lower extremity bypass, angioplasty, or major am-
putation over a 5-year period. Sixty African American major amputees were
compared with 60 white major amputees for risk of repeat amputation.
Primary and repeat amputation rates were controlled for age, sex, and
diabetes mellitus.
African American patients hospitalized for lower extremity ischemia
were younger (P  .05), more often female (P  .01), and more likely to
undergo major amputation (odds ratio, 1.68; P  .005). After adjusting
for age, sex, and diabetes prevalence, African American and white pa-
tients had an equal likelihood of primary amputation. Repeat amputees
were 2.5 times more likely to be African American than white (P  .04).
Comment: Racial disparities in revascularization versus amputation
are documented (Med Care 2002;40 Suppl:1106-16). The current study
suggests these differences may be due to severity and progression of
disease rather than access to treatment. Race, however, is clearly a
surrogate for potential cultural and socioeconomic factors that can
influence health care. Additional data evaluating effectiveness of social
support and efficacy of management of atherosclerotic risk factors in the
white versus African American amputees must be considered before
conclusions derived from this study can considered definitive rather than
speculative.
Preoperative and operative predictors of delayed neurologic deficits
following repair of thoracoabdominal aortic aneurysm
Estrera AL, Miller CC III, Huynh TTT, et al. J Thorac Cardiovasc Surg
2003;126:1288-94.
Conclusion: Acute aortic dissection, Type II thoracoabdominal (TA)
aortic aneurysms, and preoperative renal dysfunction are predictors of de-
layed neurologic deficit following thoracic and TA aortic aneurysm repair.
Summary: The authors analyzed the results of 828 consecutive
patients undergoing thoracic or TA aortic repair surviving long enough
for assessment of postoperative neurologic status. Demographic and
preoperative physiologic, as well as intraoperative, data were evaluated
with multivariable analysis to determine factors associated with delayed
neurologic deficit. Delayed neurologic deficit was defined as paraplegia
or paraparesis that occurred after a patient had recovered from anesthesia
and was initially neurologically intact.
There were 38 patients with immediate neurologic deficits and 21
(2.7%) with delayed deficits following TA aorta repair. The univariate
predictors of delayed neurologic deficit included acute dissection (odds
ratio, 3.9; P  .05), preoperative renal dysfunction (odds ratio, 5.9; P 
.06), Type II TA aorta (odds ratio, 3.0; P  .03) and use of cerebrospinal
fluid drainage and distal aortic perfusion (odds ratio, 7.7; P  .03). With a
multivariable model, cerebrospinal fluid drainage and distal aortic perfusion
were not significant. With optimization of blood pressure and cerebrospinal
fluid drainage, 12 of 21 (57%) of patients with delayed neurologic deficit
recovered neurologic function.
Comment: The risk factors identified for delayed neurologic deficit
following TA aortic repair are similar to those associated with immediate
neurologic deficit following TA aortic repair. Since reinstitution of
cerebrospinal fluid drainage results in a high rate of neurologic recovery,
the obvious question is how long should cerebrospinal fluid drainage be
maintained postoperatively to minimize development of a delayed neu-
rologic deficit?
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